EORTC GUCG YI

At what PSA level do experts recommend imaging for high-risk prostate cancer patients after radical RT and systemic therapy? The opinions are split! #Apccc24 @APCCC_Lugano @Silke_Gillessen @AOmlin @OncoAlert @ZilliThomas @cdanicas @piet_ost @yekeduz_emre @nataliagandur…

Thank you very much @BertrandTOMBAL @Silke_Gillessen @EORTC for this great opportunity! It was a privilege presenting PEACE 3 at #EMUC24 the first study (to date) to show a benefit in both rPFS and OS with ARPI combo in mCRPC. Remember the use of BPA in this setting!@OncoAlert

⁦@fabioturco92⁩ presenting PEACE3 at EMUC, great efficacy and low toxicity of Radium in early mCRPC. The ideal therapy to layer on ARPI? Probably. ⁦@EORTC⁩ ⁦@Silke_Gillessen⁩ ⁦@EORTC_GUCG_YECI⁩

#EMUC24: Congratualtions to T. Zilli, Bellinzona (CH) for his award winning abstract: "Irradiation + long-term adjuvant androgen deprivation with GnRH antagonist vs. GnRH agonist in pts with very high risk localised or locally advanced PCa: the EORTC GUCG-1414 phase 3 PEGASUS"

Congrats @ZilliThomas and to all sub investigators of the PEGASUS trial Again a crucial message on preventing new #CV event in patients with past history of #cardiovasculardisease @BertrandTOMBAL

EMUC 24 The discussion is focused on MRI as a tool for response to therapy assessment selecting pts for bladder preservation @LAUrology_NL @paolo_gontero @alexandramasson-lecomte @toinevander

I understand the enthusiasm but there is no data confirming OS gain is maintainned frontiersin.org/journals/oncol…

@ZilliThomas presenting the first results of EORTC 1414 "PEGASUS" at #EMUC24 @EORTC. Another proof that GNRH antagonists induce fewer CV events in patients with CV history than agonists. Thanks also to D. Böhmer and P. Lara.

Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 @y_loriot @Achard_Verane @vandamme_jvd @GGrisay @BertrandTOMBAL

Nice talk by @VPanebiancoIT about NacVI-RADS and how to reassess neoadjuvant treatment in MIBC !

Congrats to @vandamme_jvd @GIZZIMarcoMd for this nice poster #EMUC24 @BertrandTOMBAL

There is more than PET-PSMA to monitor tumor response in advance PCa. @vandamme_jvd @VPasoglou @FLecouvet @ProfPadhani sciencedirect.com/science/articl…

Now more than ever, it is important to propose de-escalation strategies. EORTC 2238 "De-Escalate" will address the specific question of intermittent therapy in these mHSPC patients ! @BertrandTOMBAL @Silke_Gillessen @fabioturco92 @APCCC_Lugano @EORTC @OncoAlert

The window of opportunity for patients with BCR matters ! We should start a ARpI as soon as possible in high risk BCR patients. @BertrandTOMBAL @APCCC_Lugano @APCCC24 @OncoAlert

Growing body of evidence suggests that patients with high-risk BCR should be managed with ARpI monotherapy. Side effects are manageable. the sooner the better ! Neil Shore @APCCC_Lugano @APCCC24 @OncoAlert

🩺 On @EUplatinum - Oligometastatic Bladder Cancer: Defining a Novel Entity #BladderCancer @Chrislabaki1 @DrChoueiri @eddy_saad @OncoBellmunt europeanurology.com/article/S0302-…

On y est presque!! Dans 11 jours on vous attend toutes/tous à la GFRU à Bordeaux pour le 5ème congrès international. Venez nombreux !! gfru.org/https-www-gfru…

Congrats to @tompowles1 !

⚡️ Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma #BladderCancer #Immunotherapy buff.ly/3O6YHxr

The other side of PSMA...A Case Series Study of the Role of Prostate-specific Membrane Antigen ... sciencedirect.com/science/articl…